Heghine Khachatryan on a UK Milestone: National CYP2C19 Testing Before Clopidogrel Therapy
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post by Lydia Kariuki on LinkedIn:
“Precision medicine in action: a milestone for antiplatelet therapy
The UK has taken a significant step toward truly personalized cardiovascular care by recommending routine CYP2C19 pharmacogenetic testing before initiating clopidogrel therapy within the NHS.
Clopidogrel remains a cornerstone antiplatelet agent for patients with coronary, cerebrovascular, and peripheral arterial disease. However, its clinical efficacy is highly dependent on CYP2C19-mediated bioactivation, leading to substantial inter-individual variability in response.
This national pharmacogenomic recommendation directly addresses a long-standing clinical challenge:
- reduced efficacy in CYP2C19 loss-of-function carriers
- preventable thrombotic events
- avoidable trial-and-error prescribing
Implementing PGx testing before treatment initiation allows clinicians to:
- identify non-responders early
- select alternative antiplatelet agents when appropriate
- improve outcomes while reducing complications
This is a powerful example of how pharmacogenomics can be translated into real-world clinical practice at a national level.
For countries and health systems striving to modernize cardiovascular care, this sets an important benchmark.
Precision medicine is no longer the future — it is becoming standard of care.”
Quoting Lydia Kariuki’s post:
“CYP2C19 pharmacogenetic (PGx) testing for all patients in the UK before prescribing clopidogrel
The UK has taken a major step forward in precision prescribing with the publication of its first national pharmacogenomic guideline, focused on the antiplatelet drug clopidogrel.
Clopidogrel is widely prescribed across the NHS to prevent blood clots in patients with coronary artery disease, cerebrovascular disease, and peripheral arterial disease. But while the medication is standard therapy, its effectiveness varies substantially between individuals. The new guideline directly addresses this variability by recommending CYP2C19 genotyping for patients before clopidogrel therapy is initiated.”
Stay updated and find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow